Phospho-tau217 has emerged as an excellent marker of the presence of amyloid pathology in the brain, but for markers of neurofibrillary tangles, fragments of tau’s microtubule binding region have a ...

Back in mid-June, Alzforum reported on how the AD research field was being buffeted by cuts in funding to the National Institutes of Health (Jun 2025 news; Jun 2025 news). At the time, scientists felt ...

Lithium is one of the oldest drugs in psychiatric medicine, commonly prescribed for bipolar disorder. Now, a study in the August 6 Nature lays out a new case for the potential use of this metal ...

The Dominantly Inherited Alzheimer Network has been at the vanguard of AD immunotherapy development, launching the first secondary and primary prevention trials, as well as the first study of ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Signaling through the TREM2 receptor fuels an ever-growing list of known microglial functions in the brain, and gene variants that hobble TREM2 signaling beckon Alzheimer’s disease. Ergo, activating ...

As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

In mice, mucin-domain glycoproteins on blood vessels wane with age. Boosting their abundance in old mice firmed up the blood-brain barrier. These glycoproteins also ebb in Alzheimer’s and Huntington’s ...

On September 26, 2024, the National Institute on Aging (NIA) announced that Masliah had been removed from his position as scientific director of the institute’s neuroscience division after a ...

As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association ...